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Abstract
Nanotechnologies are materials and devices that have a functional organization in at least one
dimension on the nanometer (one billionth of a meter) scale, ranging from a few to about 100
nanometers. Nanoengineered materials and devices aimed at biologic applications and medicine in
general, and neuroscience in particular, are designed fundamentally to interface and interact with
cells and their tissues at the molecular level.  One particularly important area of nanotechnology
application to the central nervous system (CNS) is the development of technologies and
approaches for delivering drugs and other small molecules such as genes, oligonucleotides, and
contrast agents across the blood brain barrier (BBB).  The BBB protects and isolates CNS
structures (i.e. the brain and spinal cord) from the rest of the body, and creates a unique
biochemical and immunological environment.  Clinically, there are a number of scenarios where
drugs or other small molecules need to gain access to the CNS following systemic administration,
which necessitates being able to cross the BBB.  Nanotechnologies can potentially be designed to
carry out multiple specific functions at once or in a predefined sequence, an important requirement
for the clinically successful delivery and use of drugs and other molecules to the CNS, and as such
have a unique advantage over other complimentary technologies and methods.  This brief review
introduces emerging work in this area and summarizes a number of example applications to CNS
cancers, gene therapy, and analgesia.
Introduction
Nanotechnologies are materials and devices that have a
functional organization in at least one dimension on the
nanometer (one billionth of a meter) scale, ranging from
a few to about 100 nanometers. Nanoengineered materi-
als and devices aimed at biologic applications and medi-
cine in general, and neuroscience in particular, are
designed fundamentally to interface and interact with
cells and their tissues at the molecular level. The potential
of nanotechnological applications to biology and medi-
cine arise from the fact that they exhibit bulk mesoscale
and macroscale chemical and/or physical properties that
are unique to the engineered material or device and not
necessarily possessed by the molecules alone. This sup-
ports the development of nanotechnologies that can
potentially carry out multiple specific functions at once or
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in a predefined sequence, which is an important property
for the clinically successful delivery of drugs and other
molecules to the central nervous system (CNS).
An ability to cross the blood-brain barrier (BBB) to deliver
drugs or other molecules (for example, oligonucleotides,
genes, or contrast agents) while potentially targeting a
specific group of cells (for instance, a tumor) requires a
number of things to happen together. Ideally, a nanode-
livery-drug complex would be administered systemically
(for example, intravenously) but would find the CNS
while producing minimal systemic effects, be able to cross
the BBB and correctly target cells in the CNS, and then
carry out its primary active function, such as releasing a
drug. These technically demanding obstacles and chal-
lenges will require multidisciplinary solutions between
different fields, including engineering, chemistry, cell
biology, physiology, pharmacology, and medicine. Suc-
cessfully doing so will greatly benefit the patient.
Although this ideal scenario has not yet been realized, a
considerable body of work has been done to develop nan-
otechnological delivery strategies for crossing the BBB.
Applications to drugs and other molecules
A significant amount of work using nanotechnological
approaches to crossing the BBB has focused on the deliv-
ery of antineoplastic drugs to CNS tumors. For example,
radiolabeled polyethylene glycol (PEG)-coated hexadecyl-
cyanoarcylate nanospheres have been tested for their abil-
ity to target and accumulate in a rat model of gliosarcoma
[1]. Another group has encapsulated the antineoplasitc
drug paclitaxel in polylactic co-glycolic acid nanoparti-
cles, with impressive results. In vitro experiments with 29
different cancer cell lines (including both neural and non-
neural cell lines) demonstrated targeted cytotoxicity 13
times greater than with drug alone [2]. Using a variety of
physical and chemical characterization methods, includ-
ing different forms of spectroscopy and atomic force
microscopy, the investigators showed that the drug was
taken up by the nanoparticles with very high encapsula-
tion efficiencies and that the release kinetics could be care-
fully controlled. Research focusing on the delivery of
many of the commonly used antineoplastic drugs is
important because most of these drugs have poor solubil-
ity under physiologic conditions and require less than
optimal vehicles, which can produce significant side
effects.
In another example, various compounds – including neu-
ropeptides such as enkephalins, the N-methyl-D-aspartate
receptor antagonist MRZ 2/576, and the chemotherapeu-
tic drug doxorubicin – have been attached to the surface
of poly(butylcyanoacrylate) nanoparticles coated with
polysorbate 80 [3-7]. The polysorbate on the surface of
the nanoparticles adsorb apolipoproteins B and E and are
taken up by brain capillary endothelial cells via receptor-
mediated endocytosis. Nanoparticle-mediated delivery of
doxorubicin is being explored in a rodent model of gliob-
lastoma [3,8]. Importantly, recent work in a rat glioblast-
oma model revealed significant remission with minimal
toxicity, setting the stage for potential clinical trials [8].
The delivery of other drugs is also being investigated.
Dalargin is a hexapeptide analog of leucine-enkephalin
containing  D-alanine, which produces CNS analgesia
when it is delivered intracerebroventricularly, but it has
no analgesic effects if it is administered systemically, spe-
cifically because it cannot cross the BBB on its own [9,10].
[3H]Dalargin was conjugated to the same poly(butylcy-
anoacrylate) nanoparticles described above, injected sys-
temically into mice, and demonstrated by radiolabeling to
cross the BBB and accumulate in brain [10]. Other, similar
studies have also demonstrated delivery of dalargin using
polysorbate 80-coated nanoparticles [11]. Other polys-
orbate 80 nanoparticles have been chemically conjugated
to the hydrophilic drug diminazenediaceturate (dimina-
zene) and proposed as a novel treatment approach for sec-
ond stage African trypanosomiasis [12]. In other work,
PEG-treated polyalkylcyanoacrylate nanoparticles were
shown to cross the BBB and accumulate at high densities
in the brain in experimental autoimmune encephalomy-
elitis [13], a model of multiple sclerosis [14,15].
For other applications, molecules other than drugs must
cross the BBB for therapeutic or diagnostic reasons,
including oligonucleotides, genes, and contrast agents.
Solid lipid nanoparticles consisting of microemulsions of
solidified oil nanodroplets loaded with iron oxide and
injected systemically into rats have been shown to cross
the BBB and accumulate in the brain with long-lasting
kinetics [16]. Iron oxides are classic superparamagnetic
magnetic resonance imaging (MRI) contrast agents.
Because iron oxides are insoluble in water, they must be
delivered as modified colloids for clinical applications,
which is usually achieved by coating them with
hydrophilic molecules, such as dextrans [17]. Therefore,
the delivery vehicle used is critical in determining the
functional properties of the contrast agent. By taking
advantage of the ability of these solid lipid nanoparticles
to cross the BBB, nanoparticles complexed with iron
oxides may provide new ways to image the CNS using
MRI.
Other work has focused on the delivery of oligonucle-
otides in an in vivo mouse model and an in vitro endothe-
lial cell model, with the aim being to develop novel
treatments for neurodegenerative disorders [18]. The
investigators synthesized a nanogel consisting of cross-
linked PEG and polyethylenimine that spontaneously
encapsulated negatively charged oligonucleotides. In theirBMC Neuroscience 2008, 9(Suppl 3):S4 http://www.biomedcentral.com/1471-2202/9/S3/S4
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in vivo model, they demonstrated that intravenous injec-
tions resulted in a 15-fold accumulation of oligonucle-
otides in the brain after 1 hour, with a concurrent twofold
decrease in accumulation in liver and spleen when com-
pared with freely administered oligonucleotides (not
encapsulated in nanogel particles).
A related area is the delivery of genes to the CNS for gene
therapy. A tyrosine hydroxylase (TH) expression plasmid
was delivered to the striatum of adult rats using PEG
immunoliposome nanoparticles in order to normalize TH
expression levels in the 6-hydroxydopamine rat model of
Parkinson's disease [19]. Using specific antibodies to
transferrin receptors conjugated to the nanoparticles, TH
plasmids were shown to be expressed throughout the
striatum.
Conclusion
Nanotechnology-based approaches to targeted delivery of
drugs and other compounds across the BBB may poten-
tially be engineered to carry out specific functions as
needed. The drug itself – in other words the biologically
active component being delivered, whatever that may be
– constitutes one element of a nanoengineered complex.
The rest of the complex is designed to carry out other key
functions, including shielding the active drug from pro-
ducing systemic side effects, being prematurely cleared or
metabolized, crossing the BBB, and targeting specific cells
after it has gained access to the CNS. Implicitly, all of this
must be achieved by any drug intended to have CNS
effects, regardless of whether it is part of a nanoengineered
complex.
An important advantage of a nanotechnological
approach, as compared with the administration of free
drug or the drug associated with a nonfunctional vehicle,
is that these critical requirements do not need to be car-
ried out by the active compound, but by supporting parts
of the engineered complex. This allows the design of the
active drug to be tailored for maximal efficacy. Currently,
most nanoengineered systems for crossing the BBB take
advantage of drugs that are already in clinical use and
therefore have greater potential for reaching the clinic rel-
atively quickly.
In addition to the delivery of drugs and other compounds
across the BBB for therapeutic purposes, the ability to
cross the BBB selectively and efficiently in animal models
using nanoengineered technologies will have a significant
impact on research that focuses on the normal physiology
of the CNS and its pathology, by allowing targeted in vivo
studies of specific cells and processes using methods that
take advantage of the intact live organism. Ideally, meth-
ods for crossing the BBB will complement other nanote-
chnological tools being developed to study the CNS,
including quantum dot labeling and imaging [20].
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